Induced pluripotent stem cell (iPSC) technologies utilizing Best disease patient-derived tissue and knock-in patient mutations have facilitated insights into the molecular mechanisms of VMD2 mutations and helped reconcile these with clinical observations. This evidence concerns the gene BEST1 and Best vitelliform macular dystrophy.